



Condensed Interim Financial Statements of

TRYP THERAPEUTICS INC.

(Unaudited - Expressed in Canadian dollars)

For the Three Months Ended November 30, 2020



TRYP THERAPEUTICS INC.

(Expressed in Canadian Dollars)

Three Months ended November 30, 2020

INDEX

Page

Notice to Readers	1
Financial Statements	
• Condensed Interim Statements of Financial Position (un-audited)	2
• Condensed Interim Statements of Loss and Comprehensive Loss (un-audited)	3
• Condensed Interim Statements of Changes in Shareholders' Equity (un-audited)	4
• Condensed Interim Statements of Cash Flows (un-audited)	5
• Condensed Interim Notes to the Financial Statements (un-audited)	6-15

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a) the accompanying unaudited condensed interim financial statements of the Company for the three months ended November 30, 2020, have been prepared by and are the responsibility of management in accordance with International Financial Reporting Standards applicable to unaudited condensed interim financial reporting.

The Company's independent auditor has not audited or performed a review of these condensed interim financial statements, in accordance with standards established by Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

TRYP THERAPEUTICS INC.**CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION (unaudited)**

As at November 30, 2020 and August 31, 2020

(Expressed in Canadian Dollars)

	Note	November 30 2020	August 31 2020
ASSETS			
Current			
Cash		\$ 682,278	\$ 1,019,100
Prepays	6,11	142,500	28,700
Taxes recoverable		11,388	-
Total current assets		836,167	1,047,800
Non current			
Deferred financing	13	198,917	26,520
Intangible assets	4	973,052	960,725
Total Assets		\$ 2,008,135	\$ 2,035,045
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current			
Trade and other payables	5	391,736	188,194
Loans from shareholders	10	-	4,514
		391,736	192,708
Shareholders' Equity			
Share Capital	6	2,399,954	2,264,954
Contributed surplus	7	162,403	-
Deficit		(945,957)	(422,617)
Total Shareholders' Equity		1,616,399	1,842,337
Total Liabilities and Shareholders' Equity		\$ 2,008,135	\$ 2,035,045

Nature of operations (note 1) and going concern (note 2)
Events after the reporting period (note 13)

Approved on behalf of the Board:

*"James Kuo" (signed)*_____
Director*"Gage Jull" (signed)*_____
Director*The accompanying notes are an integral part of these condensed interim financial statements*

TRYP THERAPEUTICS INC.**CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (unaudited)**

For the three months ended November 30, 2020

(Expressed in Canadian Dollars)

	Note	2020
General and administration	9	\$ 253,800
Marketing and Corporate Development		40,350
Research and Development		66,787
Share-based payments	7	162,403
Total expenses		(523,340)
Net loss and comprehensive loss for the period		(523,340)
Loss per share for the period- basic and diluted		\$ (0.01)
Weighted average number of shares outstanding		39,091,722

The accompanying notes are an integral part of these condensed interim financial statements

TRYP THERAPEUTICS INC.**CONDENSED INTERIM STATEMENTS OF CASH FLOWS (unaudited)**

For the three months ended November 30, 2020

(Expressed in Canadian Dollars)

	Note	2020
OPERATING ACTIVITIES		
Loss for the period		\$ (523,340)
Items not affecting cash		
Share-based payments	7	162,403
Changes in non-cash working capital		
Taxes recoverable		(11,388)
Prepaid expenses and advances		21,200
Trade and other payables		203,542
Cash used in operating activities		(147,583)
INVESTING ACTIVITIES		
Purchase of intangibles	4	(12,327)
Cash used in investing activities		(12,327)
FINANCING ACTIVITIES		
Shareholder loan re-payment	10	(4,514)
Deferred financing costs	13	(172,397)
Net cash used in financing activities		(176,911)
Decrease in cash during the period		(336,822)
Cash and cash equivalents beginning of period		1,019,100
Cash and cash equivalents end of period		\$ 682,278

Supplemental cash flow information – Note 11

The accompanying notes are an integral part of these financial statements

TRYP THERAPEUTICS INC.**CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)**

For the three months ended November 30, 2020

Expressed in Canadian Dollars

	Note	Number	Amount	Contributed Surplus	Deficit	Total
Balance September 24, 2019 (date of incorporation)		1	\$ -	\$ -	\$ -	\$ -
Repurchase and cancellation of incorporation share	6	(1)	-	-	-	-
Shares issued to founders	6	48,000	1	-	-	1
Shares issued for debt	6	666,667	50,000	-	-	50,000
Shares issued for services	6	3,792,800	189,640	-	-	189,640
Shares issued for cash	6	14,725,055	1,068,793	-	-	1,068,793
Shares issued for intangible assets	4,6	19,159,200	956,520	-	-	956,520
Net loss for the period		-	-	-	(422,617)	(422,617)
Balance August 31, 2020		38,391,722	\$ 2,264,954	\$ -	(422,617)	\$ 1,842,337
Net loss for the period		-	-	-	(523,340)	(523,340)
Share-based payments	7	-	-	162,403	-	162,403
Shares issued for services	6	900,000	135,000	-	-	135,000
Balance November 30, 2020		39,291,722	\$ 2,399,954	\$ 162,403	\$ (945,957)	\$ 1,616,400

The accompanying notes are an integral part of these financial statements

TRYP THERAPEUTICS INC.

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

1. CORPORATION INFORMATION

Nature of Operations

The Company was incorporated under *the BC Business Corporations Act* on September 24, 2019 under the name “Artos Pharma Corp.” (the “Company”). On June 30, 2020, the Company changed its name to “Tryp Therapeutics Inc”. On January 9, 2020, the Company split the common shares on the basis of two hundred (200) new shares for every one (1) common share held. On June 23, 2020, the Company consolidated the common shares on the basis of one (1) new share for every two hundred and fifty (250) common shares held. All common share information in these financial statements has been presented on a post-split and post-consolidation basis.

The Company is a clinical stage pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare or orphan diseases and other diseases with high unmet medical needs. Our lead development program, which we refer to as our psilocybin-for-neuropsychiatry, or PFN™, program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The initial indication for our PFN™ program is fibromyalgia. We are also evaluating additional indications for our PFN™ program, including hyperphagia in Prader-Willi Syndrome (“PWS”) and other neuropsychiatric-based chronic pain conditions and eating disorders.

In addition to our PFN™ program, we intend to pursue non-psychedelic drug candidates with known activity and/or safety profiles that may have utility in the treatment of rare or orphan diseases or other diseases with high unmet medical needs. As part of that program, we are developing a proprietary formulation of razoxane for the treatment of soft tissue sarcomas. We continue to evaluate additional indications for our existing programs, as well as other drug candidates that meet our criteria for development.

On December 8, 2020, the Company filed a final prospectus (the “**Prospectus**”) in British Columbia, Alberta and Ontario for an initial public offering on a best effort basis for 17,400,000 units (the “**Units**”) at a price of \$0.25 per Unit (the “Offering Price”) for gross proceeds of \$4,350,000 (the “**Offering**”) pursuant to the terms of an agency agreement (the “**Agency Agreement**”) dated December 8, 2020, between Canaccord Genuity Corp. (the “**Agent**”) and the Company. Each Unit consisting of one common share of the Company and one-half of one common share purchase warrant of the Company with an exercise price of \$0.50 for a period of 12 months following the Closing Date.

On December 17, 2020, the Company completed the Offering and issued an aggregate of 20,010,000 Units which included 2,610,000 Units following the exercise in full by the Agent of its over-allotment option, at a price of \$0.25 per Unit for aggregate gross proceeds of \$5,002,500 (See Events after the Reporting Date).

The Common Shares of Tryp commenced trading on the Canadian Securities Exchange under the symbol “TRYP” on December 18, 2020.

The Company’s principal address, records office and registered address are located at 335 – 1632 Dickson Avenue Kelowna, BC V1Y 7T2.

TRYP THERAPEUTICS INC.

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION AND GOING CONCERN

These condensed interim financial statements for the three month period ended November 30, 2020 have been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed interim financial statements follow the same accounting policies and methods of application of the Company's most recent annual financial statements. They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the Company's 2020 annual financial statements which have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"), and Interpretations of the International Financial Reporting Interpretations Committee. The condensed interim financial statements were authorized for issue by the Board of Directors on January 28, 2021.

These condensed interim financial statements have been prepared on the historical cost basis except for financial instruments measured at fair value. The condensed interim financial statements are presented in Canadian dollars ("CDN"), which is the Company's functional currency. The preparation of condensed interim financial statements in compliance with IFRS requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these condensed interim financial statements are disclosed in Note 3.

Going Concern

The Company is in the development stage and currently has no sources of cash from operations. Further funds will be required to successfully develop the Company's business and there is no certainty that these funds will be available. The Company had a net loss of \$523,340 for the three months ended November 30, 2020 and working capital of \$441,431 (August 31, 2020 - \$855,092 deficiency) and has accumulated a deficit of \$945,957 August 31, 2020 – \$422,617) since inception. The operations of the Company have primarily been funded by the issuance of common shares. The Company's continuation as a going concern is dependent upon its ability to raise equity capital or borrowings sufficient to meet current and future obligations, development and ultimately achieve profitable operations. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or results of operations at this time.

3. SIGNIFICANT ACCOUNTING POLICIES

Critical Accounting Estimates, Judgments and Assumptions

The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions. The effect of a change in an accounting estimate is recognized prospectively by including it in loss/income in the year of the change, if the change affects that year only, or in the year of the change and future years, if the change affects both.

TRYP THERAPEUTICS INC.

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (cont'd)

Information about critical judgments and estimates in applying accounting policies that have the most significant risk of causing material adjustment to the carrying amounts of assets and liabilities recognized in the financial statements within the next financial year are discussed below:

Critical accounting estimates:

Recoverability of the carrying value of intangible assets

Recoverability of the carrying value of intangible assets requires management to determine whether future economic benefits from sale or otherwise are likely. Evaluation may be more complex where activities have not reached a stage that permits a reasonable assessment of the viability of the asset. Management must make certain estimates and assumptions about future events or circumstances including, but not limited to, the interpretation of research results, as well as the Company's financial ability to continue sales activities and operations.

The measurement of deferred income tax assets and liabilities

Deferred tax assets, including those arising from un-utilized tax losses, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management's estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted.

Useful lives of intangible assets

Amortization is recorded on the straight-line basis based upon management's estimate of the useful life and residual value. The estimates are reviewed at least annually and are updated if expectations change as a result of the technical obsolescence or legal and other limits to use. A change in the useful life or residual value will impact the reported carrying value of the intangible assets resulting in a change in related amortization expense. As of November 30, 2020, the Company has not amortized the intangible assets as amortization begins when the intangible assets are available for use.

Fair value of consideration for intangible assets acquired

The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration in the acquisition of intangible assets. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services for share-based payments made to those other than employees or others providing similar services.

Critical accounting judgments:

Going concern

The preparation of these financial statements requires management to make judgments regarding the going concern of the Company as discussed in note 2.

TRYP THERAPEUTICS INC.
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)
For the Three Months ended November 30, 2020
(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (cont'd)

Critical accounting judgments: (cont'd)

Treatment of development costs

Costs to develop products are capitalized to the extent that the criteria for recognition as intangible assets in IAS 38 *Intangible Assets* are met. Those criteria require that the product is technically and economically feasible, which management assessed based on the attributes of the development project, perceived user needs, industry trends and expected future economic conditions. Management considers these factors in aggregate and applies significant judgment to determine whether the product is feasible. The Company has not capitalized any development costs as of November 30, 2020.

Treatment of deferred financing costs

Professional, consulting, regulatory and other costs directly attributable to financing transactions are recorded as deferred financing costs until the financing transactions are completed, if the completion of the transaction is considered likely; otherwise they are expensed as incurred. Management applies significant judgment to determine whether the completion of the transaction is considered likely.

Treatment of acquired intangible assets

Consideration paid in the acquisition of intangible assets is capitalized to the extent that the definition of an intangible asset and the criteria for recognition as intangible assets in IAS 38 *Intangible Assets* are met. Those criteria require that the intangible asset be identifiable, the Company must have control over it, and it must provide future economic benefits. Management considers these factors in aggregate and applies significant judgment to determine whether the intangible asset should be recognized in the statement of financial position.

At each reporting date, the Company assesses if the intangible assets have indicators of impairment. In determining whether the intangible assets are impaired, the Company assesses certain criteria, including observable decreases in value, significant changes with adverse effect on the entity, evidence of technological obsolescence and future plans.

4. INTANGIBLE ASSETS

During the period ended November 30, 2020, the Company invested \$12,327 (August 31, 2020 - \$960,725) in intellectual property as follows:

	Intellectual Property
Costs	
Balance at September 24, 2019	-
Additions – Note 6	\$ 960,725
Balance August 31, 2020	960,725
Additions	12,327
Balance November 30, 2020	\$ 973,052

TRYP THERAPEUTICS INC.**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)**

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

4. INTANGIBLE ASSETS (cont'd)

On January 9, 2020, the Company and a director entered into a purchase and assignment agreement (the "IP Purchase Agreement") pursuant to which the Company acquired certain inventions, technical information and patent application (the "Purchase Assets"). Pursuant to the terms of the IP Purchase Agreement, the Company issued 32,000 common shares at a price of \$0.005 per common share for a value of \$160 for the Purchased Assets.

On June 23, 2020 the Company entered into purchase agreements (collectively the "Additional IP Purchase Agreements") with the directors of the Company pursuant to which to which the Company acquired certain inventions, technical information and patent application (the "Additional Purchase Assets"). Pursuant to the terms of the Additional IP Purchase Agreements, the Company issued and aggregate of 19,127,200 common shares at a price of \$0.05 per common share for an aggregate value of \$956,360 for the Additional Purchased Assets.

5. TRADE AND OTHER PAYABLES

	November 30 2020	August 31 2020
Trade payables	\$ 333,935	\$ 141,081
Due to related parties - Note 10	57,801	47,113
Total	\$ 391,736	\$ 188,194

6. SHARE CAPITAL**Authorized share capital**

The Company's authorized share capital consists of:

Unlimited common shares without par value.

Unlimited preferred shares without par value.

As at November 30, 2020, the Company had 39,291,722 common shares issued and outstanding and no preferred shares issued and outstanding.

Issued and outstanding

During the period ended November 30, 2020, the Company issued the following:

On September 21, 2020 the Company issued 900,000 common shares at \$0.15 per common share with a fair value of \$135,000 as shares for debt for marketing and corporate development services.

During the period from incorporation of September 24, 2019 to August 31, 2020 the Company issued the following:

On September 24, 2019, the Company issued an incorporation share at \$1 per share.

On September 24, 2019, the Company repurchased and cancelled the incorporation share and issued 48,000 founder's shares at \$0.000001 per share for total proceeds of \$1.

TRYP THERAPEUTICS INC.

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

6. SHARE CAPITAL (cont'd)

On January 3, 2020, the Company issued 32,000 common shares at \$0.005 per common share with a value of \$160 for intellectual property purchased.

On June 30, 2020, the Company issued 3,792,800 common shares at \$0.05 per common share with a fair value of \$189,640 for past services to consultants, and an officer.

On June 30, 2020, the Company issued 19,127,200 common shares at \$0.05 per common share with a fair value of \$956,360 for Intellectual Property purchased.

On August 4, 2020, the Company completed a non-brokered private placement of 11,399,650 common shares at a price of \$0.05 per common share for gross proceeds of \$569,982.

On August 4, 2020, the Company issued 500,000 common shares at \$0.05 per common share with a fair value of \$25,000 as shares for debt for marketing and corporate development services.

On August 14, 2020, the Company issued 166,667 common shares at \$0.15 per common share with a value of \$25,000 as shares for debt for marketing and corporate development services.

In August 2020, the Company completed a non-brokered private placement in two tranches for an aggregate of 3,325,405 common shares at a price of \$0.15 per common share as follows:

- i) August 14, 2020 – 2,825,405 for gross proceeds of \$423,811; and
- ii) August 31, 2020 – 500,000 common shares for gross proceeds of \$75,000.

7. SHARE-BASED PAYMENTS

Option Plan Details

On January 9, 2020, the Company implemented an Incentive Stock Option Plan (the "Stock Option Plan"). Pursuant to the Stock Option Plan, the Company will grant stock options to directors, officers, employees and consultants for services, provided that the number of common shares reserved for issuance shall not exceed 10% of the issued and outstanding common shares exercisable for a period of up to 10 years. The exercise price and vesting terms of the options granted under the Stock Option Plan will be determined by the Board of Directors.

Options

The following is the summary of changes in options from the period ended September 24, 2019 and November 30, 2020:

	Number of Options	Weighted Average Exercise Price
Balance, August 31, 2020	-	\$-
Granted	6,869,684	\$0.15
Balance, November 30, 2020	6,869,684	\$0.15

TRYP THERAPEUTICS INC.**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)**

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

7. SHARE-BASED PAYMENTS (cont'd)**Options (cont'd)**

As at November 30, 2020, 6,869,684 (August 31, 2020 – Nil) options were outstanding and exercisable with a weighted average remaining contractual life of 7.65 (August 31, 2020 – Nil) years.

Expiry Date	Exercise Price	Number of Options	Vested and Exercisable	Unvested
September 29, 2025	\$0.15	1,600,000	133,333	1,466,667
November 2, 2025	\$0.15	1,500,000	180,556	1,319,444
November 2, 2030	\$0.15	3,769,684	76,936	3,692,748
		6,869,684	390,825	6,478,859

a) Fair Value of Options Issued During the Period

During the period ended November 30, 2020, the weighted average fair value at grant date of options granted was \$0.15 per option. During the period ended November 30, 2020, there were 6,689,684 options granted. As of November 30, 2020, 6,689,684 options were outstanding of which 390,825 were exercisable under the Plan with a weighted average contractual life of 5.9 years with the remaining 6,478,859 unvested options with an average contractual life of 7.8 years remaining.

b) Expenses Arising from Share-based Payment Transactions

The fair value of the options was determined using the following Black-Scholes Option Pricing model assumptions:

	November 30 2020
Share price	\$0.15
Exercise price	\$0.15
Expected life	5 – 10 years
Volatility	100%
Risk-free interest Rate	0.36% - 0.70%

The total fair value of options issued during the period ended November 30, 2020 was \$846,978 (2019 - \$Nil) of which \$162,403 has been recorded as a share-based payment expense in the statements of loss with a corresponding increase in contributed surplus. The remaining amount of \$684,575 will be expensed as the remaining unvested options vest.

TRYP THERAPEUTICS INC.**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)**

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

8. ADMINISTRATIVE AND GENERAL EXPENSES

	Note	Three Months Ended November 30 2020
Administrative and General Expenses		
Professional fees		\$ 66,558
Consulting	9	114,310
Website, advertising, shareholder communication		51,986
Office and administration fees		4,605
Regulatory fees		16,341
		\$ 253,800

9. KEY MANAGEMENT AND PERSONNEL COMPENSATION

Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Company's Board of Directors and corporate officers. Key management personnel compensation for the period November 30, 2020, including Company officers, directors, and private companies controlled by officers and directors, was as follows:

	November 30 2020
Key management personnel compensation comprised:	
Consulting fees:	\$40,810
Share-based payments	10,272
	\$51,082

Share-based payments are the fair value of options granted to key management personnel.

As of November 30, 2020, included in trade and other payables are amounts due to officers and directors for fees and expenses of \$57,801 (August 31, 2020 - \$41,113).

Amounts due to related parties included in trade and other payables are unsecured, non-interest bearing and are without fixed terms of repayment.

10. RELATED PARTY TRANSACTIONS**Shareholder loans**

As at November 30, 2020 cash advances to the Company in the amount of \$Nil (August 31, 2020 - \$4,514) was due and payable to a director and shareholder of the Company. This amount is due on demand, unsecured, and without interest.

TRYP THERAPEUTICS INC.

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

11. SUPPLEMENTAL CASH FLOW INFORMATION

	Note	November 30 2020
Non-cash investing and financing activities	(i)	\$135,000
	(ii)	\$122,396

- (i) As outlined in note 6, the Company issued a 900,000 common shares of the Company with a fair value of \$135,000 in connection with compensation for marketing and corporate development which was recorded in prepaids.
- (ii) Deferred financing costs included in trade and other payables.

12. SEGMENTED INFORMATION

The Company operates in one business segment being the clinical stage pharmaceutical research and development company. All assets of the Company are located in Canada.

13. EVENTS AFTER THE REPORTING DATE

Stock Options

On December 22, 2020, the Company granted 400,000 stock options at an exercise price of \$0.75 for a period of 10 years to directors of the Company. The options vest 50% on date of grant and the remaining balance over a period of 12 months.

On January 13, 2021, the Company granted 200,000 stock options at an exercise price of \$0.75 for a period of 10 years to a director of the Company. The options vest 50% on date of grant and the remaining balance over a period of 12 months.

Warrants

On January 21, 2021, the Company issued 135,000 common shares pursuant to the exercise of warrants at a price of \$0.50 per share for proceeds of \$67,000.

Initial Public Offering

As described in Note 1, in connection with the completion of the Offering, the Company issued an aggregate 20,010,000 Units at a price of \$0.25 per Unit for aggregate gross proceeds of \$5,002,500.

Each Unit consists of one common share in the capital of the Company (each a "**Common Share**") and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "**Warrant**"). Each Warrant is exercisable into one Common Share (each, a "**Warrant Share**") at an exercise price of \$0.50 per Warrant Share at any time prior to 5:00 p.m. (Vancouver time) on December 16, 2021, subject to acceleration in certain events.

TRYP THERAPEUTICS INC.

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)

For the Three Months ended November 30, 2020

(Expressed in Canadian Dollars)

13. EVENTS AFTER THE REPORTING DATE (cont'd)

Pursuant to the terms and conditions of the Agency Agreement, the Company has paid the Agent a of equal to 8% of the gross proceeds of the Offering plus a 4% commission on the presidents list (the "**Agent's Fee**") in cash and compensation options (an "**Agent's Options**"). Pursuant to the Agent's Fee the Company paid an aggregate cash amount of \$360,800 and issued 1,443,000 Agent's Options. Each Agent Option is exercisable into one Common Share (each, an "**Agent Option Share**") at an exercise price of \$0.25 per Agent Option Share at any time prior to 5:00 p.m. (Vancouver time) on December 16, 2021, subject to acceleration in certain events.

Additionally, the Company paid a corporate finance fee of 5% of the of the aggregate number of Units issued pursuant to the Offering (the "**Corporate Finance Fee**"). Pursuant to the Corporate Finance Fee the Company issued an aggregate 1,000,500 common shares and 500,250 Agent warrants (an "**Agent Warrant**"). Each Agent Warrant is exercisable into one Common Share (each, an "**Agent Warrant Share**") at an exercise price of \$0.50 per Agent Warrant Share at any time prior to 5:00 p.m. (Vancouver time) on December 16, 2021, subject to acceleration in certain events.

As at November 30, 2020, included in deferred financing costs is an amount of \$198,917 for professional fees incurred in relation to the Prospectus.